

The ACT-Accelerator

Status & urgent priorities

World Health Assembly

9 November 2020

Access to COVID-19 Tools Accelerator launch 24 April

Objectives

tests, treatments & vaccines

equitable global access

With:

UN Secretary-General

Heads of State & Government, Heads of Agencies

Academia, Industry, CSOs, Foundations



ACT-A has already **achieved key landmarks**

(examples at 9 Nov 2020)



New Rapid Tests approved, with volume & price guarantees for LICs/LMICs (120m tests @ \$3-5/unit over 6 months)



1st life-saving therapy in rollout (Dexamethasone) with 3 M doses for LICs; **monoclonal antibodies** in evaluation for LICs




COVAX Facility ‘in business’ with 186+ economies (>90% of world population); dynamic vaccine portfolio




Equitable Allocation Framework & COVAX Allocation Mechanism established

ACT-A is helping to **save lives with these tools & accelerate other game-changing products** in the coming months


Increasing disease severity




Pre ACT-A



by November



by March 2021




XXX New tool



ACT Accelerator
ACCESS TO COVID-19 TOOLS

But **access to these critical tools differs widely across countries** & could worsen without urgent financial & political action



PPE = Personal Protective Equipment, PCR = Polymerase Chain Reaction, Dexa = Dexamethasone, RDT = Rapid Diagnostic Test, mAbs = Monoclonal Antibodies

ACT-A's urgent priorities aim to start changing the fundamental dynamic of the pandemic by March



Diagnostics

Expanded testing globally: with immediate increase in the number & volume of high-quality RDTs and facilitating their use



Therapeutics

Wider availability of treatments to save lives: by accelerated use of Dexamethasone & oxygen and secured production capacities for mAbs



Vaccines

Full vaccination readiness: with doses secured for global rollout to +20% of population; further R&D, tech transfer & capacity scale-out




Health systems connector

Best practice for delivering COVID-19 tools established and in roll out: with rapid assessments, integrated delivery plans, large scale PPE use and key systems investments

Closing ACT-A's urgent US\$4.5 B financing gap is crucial for it's nearterm priorities, scale-up & impact

Evolution of ACT-A funding need –\$US B



Urgent ACT-A financing gap per Pillar –\$US B

Pillar	Gap (US\$ B)
Diagnostics	1.1
Therapeutics	0.75
Vaccines	1.0
HS Connector	1.7
TOTAL	4.5

1. incl. US\$ 150 M by Gavi for Vaccine Procurement/Delivery; 2. COVAX Facility manufacturing & procurement costs financed by self-financing participants (SFP) [List of SFPs](#)

"...if medical solutions can be made available faster and more widely relative to our baseline, it could lead to a cumulative increase in global income of almost \$9 trillion by end-2025"

IMF World Economic Outlook, October 2020

Addressing ACT-A's urgent needs = only **1 day** of that income and would save countless lives